Immunotech Biopharm Ltd. (6978)

Overview

Immunotech Biopharm Ltd stands out in the biopharmaceutical industry with its specialized focus on cellular immunotherapy for cancer treatment within the People's Republic of China. Since its inception in 2006 and with its headquarters in Beijing, the company has been at the forefront of developing T cell immunotherapy products, aiming to revolutionize cancer treatments. Leveraging advanced biotechnological research and development capabilities, Immunotech Biopharm strives to create innovative solutions for combating various kinds of cancers through cutting-edge cellular immunotherapy techniques.

Products and Services

• EAL: Acting as Immunotech Biopharm's flagship product, EAL is a multi-target cellular immunotherapy product that has currently reached Phase II clinical trials specifically for preventing the postsurgical recurrence of liver cancer. Beyond liver cancer, EAL is being explored in pre-clinical and clinical trials for potential treatments against lung cancer, glioma, gastric cancer, and colorectal cancer, showcasing its versatility and broad application spectrum in oncology.
• 6B11-OCIK Injection: This innovative therapy is currently undergoing Phase I clinical trials targeting ovarian cancer. It represents Immunotech's commitment to diversifying its portfolio to include treatments for a variety of cancer types.
• CAR-T-19 Injection: Designed for B-cell acute lymphoblastic leukaemia, the CAR-T-19 injection signifies the company's engagement in harnessing CAR-T cell technology for blood cancers, evidencing their expertise in cellular immunotherapies.
• RC19D2: This product is tailored for patients with non-hodgkin lymphoma, illustrating Immunotech's endeavor to broaden its impact across different hematological malignancies.
• TCR-T Cell Series Products: Aimed at treating solid tumors, these products highlight the company’s efforts in tackling the more challenging aspect of cancer treatment, where traditional therapies often falter. It signifies a step towards personalized medicine in oncology.
• Pre-Clinical Products:
  • aT19 - Specifically designed to combat acute lymphoblastic leukemia, showing Immunotech's ongoing research initiatives.
  • CAR-T-43 - Targets T cell leukemia and lymphoma, further diversifying the company's portfolio within hematological cancers.
  • CAR-T-22 - Focused on B lymphocyte leukemia, showcasing advancements in treatments for specific blood cancer subtypes.
  • CAR-T-BCMA - For multiple myeloma, representing the company's venture into more specialized CAR-T cell therapies.
  • CAR-T-ENX - A promising solid tumor treatment, advancing the scope of CAR-T technology beyond hematological malignancies.
  • TCR800 - Targets renal cancer, showing the expanding capabilities of TCR-T cell therapies in Immunotech’s arsenal.
  • EBV, CMV Specific T Cells - Designed for EBV/CMV infections, these products showcase the potential of targeted cellular therapies in infectious diseases, further highlighting Immunotech's versatility in cellular therapy applications.